AbbVie

AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas –immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on X, Facebook, Instagram, YouTube, LinkedIn and Tik Tok.

1 North Waukegan Road
North Chicago, IL 60064

Visit website

Stock Symbol: ABBV
Stock Exchange: NYSE

Together, we break through.

Our principles are at the Heart of our Company. Operating as one AbbVie team, we care deeply for our patients, their families, our employees, and our communities. We strive to always do the right thing, pursuing the highest standards in quality, compliance, safety, and performance. In everything we do, we invest and innovate relentlessly to tackle unmet needs, creating new medicines and healthcare approaches for a healthier world.

How we work with each other and achieve results matters. That’s why we’ve been honored to receive some of the most prestigious ratings and recognitions in the industry, including being named on more than 40 Great Place to Work and Top Employer lists and FORTUNE “100 Best Companies to Work For.”

Click here to learn more about our principles.

NEWS

Shire Under Pressure to Break Up the Business

Deals

UPDATED: Shire Rejects Takeda’s $60 Billion Acquisition Bid and Allergan Reportedly In Talks with Shire

Takeda Pharmaceutical has made an official bid to acquire London’s Shire for about $60 billion. And in breaking news, Shire rejected the bid, saying it undervalued the company.

April 19, 2018

4 min read

Mark Terry

Black clock with Review time, three-dimensional rendering, 3D illustration

Drug Development

FDA Pushes Back PDUFA Date for AbbVie’s Endometriosis Drug

The U.S. Food and Drug Administration wants more time to review AbbVie’s elagolix, a treatment for endometriosis-associated pain.

April 11, 2018

2 min read

Alex Keown

indecisive man and lost chooses the right path

Drug Development

Pipeline Concerns: Four Biotechs to Keep Your Eye On

When a pipe in someone’s house breaks or leaks it can cause a lot of damage to the property if it is not addressed in a timely manner. The same can be said for the pipelines of biopharma companies.

April 11, 2018

3 min read

Alex Keown

The 7 Best Life Science Companies to Work for in 2

BioMidwest

Survey Says These Five Biotech Companies are Top Places to Work

There are a lot of factors that must come together in order to make a “great” workplace. A new report suggests that two of the key features of a great workplace are a “strong sense of purpose and lived-out values.”

April 10, 2018

3 min read

Alex Keown

Money in the jar on wooden table with filter effect retro vintage style. Money and business concept

New Database Tracks Pharma Donations to Patient Advocacy Groups

The relationship between pharmaceutical companies and patient advocacy groups is long and deep and involves millions of dollars in donations, a new report reveals.

April 10, 2018

3 min read

Alex Keown

Drug Development

AbbVie’s Arthritis Drug Dazzles in Phase III Trial

AbbVie announced positive top-line data from its Phase III SELECT-COMPARE clinical trial of upadacitinib in moderate to severe rheumatoid arthritis.

April 9, 2018

3 min read

Mark Terry

Business

UPDATED: FDA Issues CLRs for Two Celltrion and Teva Biosimilars

The FDA issued two Complete Response Letters (CRLs) to South Korean manufacturer Celltrion. Teva Pharmaceutical Industries signed a deal in 2016 with Celltrion to commercialize the two biosimilars.

April 6, 2018

3 min read

Mark Terry

Intellectual Property word cloud over white background

Business

AbbVie Strikes Deal: Blockbuster Humira is Safe Until 2023

U.S. sales of AbbVie’s blockbuster Humira is safe from a biosimilar challenge from Samsung Bioepis, a joint project between Samsung and Biogen, until 2023.

April 5, 2018

2 min read

Alex Keown